Warner Chilcott PLC (WCRX): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Warner Chilcott ( WCRX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.2%. By the end of trading, Warner Chilcott rose $0.49 (2.3%) to $21.86 on light volume. Throughout the day, 3,496,429 shares of Warner Chilcott exchanged hands as compared to its average daily volume of 5,736,400 shares. The stock ranged in a price between $21.39-$22.08 after having opened the day at $21.39 as compared to the previous trading day's close of $21.37. Other companies within the Health Care sector that increased today were: Skystar Bio-Pharmaceutical Company ( SKBI), up 82.5%, Columbia Laboratories ( CBRX), up 17.1%, GW Pharmaceuticals PLC ADR ( GWPH), up 16.9% and Anacor Pharmaceuticals ( ANAC), up 15.9%.

Warner Chilcott Public Limited Company, a specialty pharmaceutical company, engages in the development, manufacture, promotion, and franchise of branded pharmaceutical products focusing on the women's healthcare, gastroenterology, urology, and dermatology markets. Warner Chilcott has a market cap of $5.3 billion and is part of the drugs industry. Shares are down 2.1% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Warner Chilcott a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Warner Chilcott as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that revenues have generally been declining.

On the negative front, Mast Therapeutics ( MSTX), down 42.2%, Biolase ( BIOL), down 33.7%, Spherix ( SPEX), down 19.1% and IMRIS ( IMRS), down 15.9% , were all laggards within the health care sector with Questcor Pharmaceuticals ( QCOR) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

The Next Oil Boom: Excitement About Alaskan Crude Builds

The Next Oil Boom: Excitement About Alaskan Crude Builds

Citi Tops Trading Rivals as JPMorgan, Bank of America Falter

Citi Tops Trading Rivals as JPMorgan, Bank of America Falter

Would a Porsche IPO Price Double Like Ferrari's Did?

Would a Porsche IPO Price Double Like Ferrari's Did?

Dow Surges as Strong Earnings Push the Blue-Chip Index Higher, Nasdaq Rises 2%

Dow Surges as Strong Earnings Push the Blue-Chip Index Higher, Nasdaq Rises 2%

Is Uber Really Worth More Than GM, Ford and Fiat Combined?

Is Uber Really Worth More Than GM, Ford and Fiat Combined?